In modern metabolic and hormonal care, an important question is increasingly being asked: can GLP-1–based therapies such as Mounjaro be used safely and effectively alongside hormone replacement therapy (HRT)?

We are currently witnessing a major shift in the management of obesity, type 2 diabetes, and menopausal health. 

GLP-1 receptor agonists are transforming metabolic care by promoting…

• Weight loss
• Improving insulin sensitivity
• Reducing cardiovascular risk. 

At the same time, hormone replacement therapy remains central to managing menopausal symptoms and estrogen deficiency, with well-established benefits for bone health, fat distribution, and vascular function.

This article explores the individual roles of GLP-1 therapies and HRT, examines emerging evidence on their combined use, and discusses important clinical considerations when using them together.

Overview of GLP-1 receptor agonists

GLP-1 (Glucagon-like-peptide-1)is a hormone released from the gut after eating.

It does….

• Stimulates insulin secretion
• Suppresses glucagon release
• Slows gastric emptying
• Increases feelings of fullness.

Medications that mimic GLP-1, such as liraglutide, semaglutide (Ozempic/Wegovy), and tirzepatide (Mounjaro), enhance these effects. 

Mounjaro is a dual agonist, activating both GLP-1 and GIP receptors, leading to more potent metabolic benefits.

Clinical trials have consistently shown significant weight loss, improved glycaemic control, and reduced cardiovascular risk with these agents. 

Beyond glucose-lowering, GLP-1 therapies improve insulin sensitivity and positively affect fat and muscle metabolism, making them valuable tools in the treatment of obesity and type 2 diabetes.

Understanding Hormone Replacement Therapy (HRT)

Hormone replacement therapy is primarily used to manage menopausal symptoms resulting from the natural decline in ovarian hormones, estrogen and progesterone. 

These symptoms include…

• Hot flashes
• Night sweats
• Vaginal dryness
• Mood changes
• Sleep disturbances. 

Hormonal replacement therapy helps replenish declining hormonal levels and alleviate these symptoms, thereby improving the quality of life in menopausal individuals.

HRT is also essential in women with Premature Ovarian Insufficiency, where estrogen deficiency occurs before the age of 40. 

In this group, hormone replacement helps preserve bone health, cardiovascular function, and cognitive wellbeing until the natural age of menopause.

Combined Use – Interventions and Synergy

A key consideration is whether GLP-1 therapies and HRT complement each other. Emerging evidence suggests potential synergy. 

Experimental studies indicate that estrogen and GLP-1 receptor agonists may influence shared metabolic pathways involved in appetite regulation, energy expenditure, and fat distribution. 

Oestrogen plays a crucial role in metabolic regulation, and oestrogen deficiency during menopause is associated with increased central adiposity and insulin resistance. 

Restoring estrogen through HRT may therefore support metabolism and appetite in postmenopausal women.

It is also important to note that large-scale clinical trials investigating the combined use of GLP-1 receptor agonists and hormonal replacement therapy are still lacking. 

Most of the current evidence stems from laboratory studies or small-scale observations. 

As healthcare providers, close monitoring of patients undergoing combined therapy is essential to ensure safety and efficacy.

Risks, Benefits, and Clinical Considerations

In medical practice, any combined treatments must balance benefits and risks. 

GLP-1 receptor agonists are generally well-tolerated, but common side effects include digestive symptoms such as nausea, vomiting, or diarrhoea, especially when starting a GLP-1 drug. 

These symptoms improve over time or with dose adjustments.

In contrast, Hormonal Replacement Therapy carries different risks. 

It also modestly increases the risk of blood clots and stroke in susceptible women. 

That is why it is important to screen carefully for personal or family history of clotting disorders, smoking, or uncontrolled hypertension for women considering hormonal replacement therapy. 

When using GLP-1 together with HRT, these safety issues add up.

For example, both therapies can slightly raise the resting heart rate, so patients should be cautious with those who have a history of certain heart conditions. 

On the other hand, both therapies improve insulin sensitivity and weight management, which is potentially a powerful combination for women who are struggling with menopausal weight gain and metabolic syndrome. 

Both GLP-1 agonists and hormonal replacement therapy have clear benefits but also specific contraindications, so it is important to discuss a patient’s overall health, preferences, and goals.

Summary

The combined use of GLP-1 receptor agonists, including Mounjaro, and hormone replacement therapy represents a promising approach to managing the interconnected challenges of metabolic dysfunction and hormonal decline in midlife women. 

GLP-1 therapies reduce appetite, improve glycaemic control, and promote weight loss, while HRT relieves menopausal symptoms, preserves bone density, and supports metabolic health.

However, this combination must be approached with clinical judgement. 

Treatment decisions should be personalised, taking into account menopausal status, cardiometabolic risk, symptom burden, and individual health goals. 

When carefully selected and monitored, GLP-1 therapy and HRT can indeed work hand in hand to improve both quality of life and long-term health during this important life transition.


Hema, is a Specialist Dietitian at The London Obesity & Endocrine Clinic. She has helped many patients overcome weight management barriers. ©Simplyweight

Top obesity clinic in Chennai